Takahashi, H., & Shimoyama, N. (2010). A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. International Journal of Clinical Oncology, 15, 46–51.doi: 10.1007/s10147-009-0009-1
To assess the usefulness of gabapentin in the treatment of cancer-related neuropathic pain
Patients who met the eligibility criteria of a score of 5 or greater on a numeric pain rating scale were entered. Gabapentin was begun at baseline at 200 mg and titrated to a maximum dose of 2,400 mg per day. Patients were asked to keep a pain diary and were assessed by a clinician throughout the 15-day study period.
The study was conducted in a single-site inpatient setting in Japan.
This was an open-label, prospective study.
Measurements included a numeric pain rating scale using the Brief Pain Inventory, the McGill Pain Questionnaire, a numeric pain relief scale, and the Patient Global Impression of Change scale.
A significant reduction was noted at various time points for worst, least, and average pain on the numeric scale (p < 0.004). Mean change in scores from baseline ranged from 0.6 to 1.3. No differences were found in any other outcome measure.
A statistical reduction in pain occurred as measured on the five-point numeric rating scale; however, the change was relatively small.
The study findings do not provide strong support for the effectiveness of gabapentin for the management of cancer-related neuropathic pain or other symptoms.